Cargando…
A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects
Background: Several neurobiological mechanisms have been proposed to support the hypothesis of a higher COVID-19 risk in individuals with autism spectrum disorder (ASD). However, no real-world data are available on this population. Methods: We compared the period prevalence (March–May 2020) and symp...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301977/ https://www.ncbi.nlm.nih.gov/pubmed/34203463 http://dx.doi.org/10.3390/brainsci11070860 |
_version_ | 1783726796925042688 |
---|---|
author | Brondino, Natascia Bertoglio, Federico Forneris, Federico Faravelli, Silvia Borghesi, Alessandro Damiani, Stefano Provenzani, Umberto Nola, Marta Olivola, Miriam Caviglia, Monica Politi, Pierluigi Fusar-Poli, Laura Fusar-Poli, Paolo |
author_facet | Brondino, Natascia Bertoglio, Federico Forneris, Federico Faravelli, Silvia Borghesi, Alessandro Damiani, Stefano Provenzani, Umberto Nola, Marta Olivola, Miriam Caviglia, Monica Politi, Pierluigi Fusar-Poli, Laura Fusar-Poli, Paolo |
author_sort | Brondino, Natascia |
collection | PubMed |
description | Background: Several neurobiological mechanisms have been proposed to support the hypothesis of a higher COVID-19 risk in individuals with autism spectrum disorder (ASD). However, no real-world data are available on this population. Methods: We compared the period prevalence (March–May 2020) and symptom presentation of COVID-19 infections between a sample of individuals with severe ASD (n = 36) and the staff personnel (n = 35) of two specialized centers. Anti-SARS-Cov-2 antibody positivity was used as a proxy of infection. Additionally, we evaluated vaccine side effects in the same groups. Results: No significant difference was found between the prevalence of COVID-19 positivity between autistic participants and staff personnel. Levels of antibodies against the spike protein and the receptor binding domain were not significantly different between autistic and staff participants. The level of antibodies against the N-terminal domain were higher in autistic individuals. There was a significant difference between the prevalence of symptomatic COVID-19 in autistic participants (9.1%) compared to staff personnel (92.3%). The most frequent side effect among autistic participants was light fever. Conclusions: The present study provides preliminary data on COVID-19 transmission and presentation in ASD. Our data do not support the hypothesis of a higher susceptibility and severity of COVID-19 in people with ASD. |
format | Online Article Text |
id | pubmed-8301977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83019772021-07-24 A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects Brondino, Natascia Bertoglio, Federico Forneris, Federico Faravelli, Silvia Borghesi, Alessandro Damiani, Stefano Provenzani, Umberto Nola, Marta Olivola, Miriam Caviglia, Monica Politi, Pierluigi Fusar-Poli, Laura Fusar-Poli, Paolo Brain Sci Article Background: Several neurobiological mechanisms have been proposed to support the hypothesis of a higher COVID-19 risk in individuals with autism spectrum disorder (ASD). However, no real-world data are available on this population. Methods: We compared the period prevalence (March–May 2020) and symptom presentation of COVID-19 infections between a sample of individuals with severe ASD (n = 36) and the staff personnel (n = 35) of two specialized centers. Anti-SARS-Cov-2 antibody positivity was used as a proxy of infection. Additionally, we evaluated vaccine side effects in the same groups. Results: No significant difference was found between the prevalence of COVID-19 positivity between autistic participants and staff personnel. Levels of antibodies against the spike protein and the receptor binding domain were not significantly different between autistic and staff participants. The level of antibodies against the N-terminal domain were higher in autistic individuals. There was a significant difference between the prevalence of symptomatic COVID-19 in autistic participants (9.1%) compared to staff personnel (92.3%). The most frequent side effect among autistic participants was light fever. Conclusions: The present study provides preliminary data on COVID-19 transmission and presentation in ASD. Our data do not support the hypothesis of a higher susceptibility and severity of COVID-19 in people with ASD. MDPI 2021-06-28 /pmc/articles/PMC8301977/ /pubmed/34203463 http://dx.doi.org/10.3390/brainsci11070860 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Brondino, Natascia Bertoglio, Federico Forneris, Federico Faravelli, Silvia Borghesi, Alessandro Damiani, Stefano Provenzani, Umberto Nola, Marta Olivola, Miriam Caviglia, Monica Politi, Pierluigi Fusar-Poli, Laura Fusar-Poli, Paolo A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects |
title | A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects |
title_full | A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects |
title_fullStr | A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects |
title_full_unstemmed | A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects |
title_short | A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects |
title_sort | pilot study on covid and autism: prevalence, clinical presentation and vaccine side effects |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301977/ https://www.ncbi.nlm.nih.gov/pubmed/34203463 http://dx.doi.org/10.3390/brainsci11070860 |
work_keys_str_mv | AT brondinonatascia apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT bertogliofederico apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT fornerisfederico apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT faravellisilvia apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT borghesialessandro apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT damianistefano apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT provenzaniumberto apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT nolamarta apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT olivolamiriam apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT cavigliamonica apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT politipierluigi apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT fusarpolilaura apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT fusarpolipaolo apilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT brondinonatascia pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT bertogliofederico pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT fornerisfederico pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT faravellisilvia pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT borghesialessandro pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT damianistefano pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT provenzaniumberto pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT nolamarta pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT olivolamiriam pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT cavigliamonica pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT politipierluigi pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT fusarpolilaura pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects AT fusarpolipaolo pilotstudyoncovidandautismprevalenceclinicalpresentationandvaccinesideeffects |